Literature DB >> 7586334

Genetic linkage of the ACE gene to plasma angiotensin-converting enzyme activity but not to blood pressure. A quantitative trait locus confers identical complex phenotypes in human and rat hypertension.

R Kreutz1, N Hübner, D Ganten, K Lindpaintner.   

Abstract

BACKGROUND: An allelic variant of the ACE gene has been found to be linked to plasma angiotensin-converting enzyme (ACE) activity in humans and has been implicated in the etiology of some common cardiovascular disorders. Previously, we have shown significant genetic linkage of blood pressure to a region on rat chromosome 10 that contains ACE in an experimental F2-intercross between the stroke-prone spontaneously hypertensive rat (SHRSPHD) and the normotensive Wistar-Kyoto (WKYHD-0) reference strain. Subsequent investigations revealed marked differences in plasma ACE activity among the SHRSPHD and WKYHD-0 strains. Nonetheless, the physiological relevance of these findings remained obscure. We therefore investigated the genetic determination of plasma ACE activity and its relation to blood pressure and dietary NaCl exposure in a model of experimental genetic hypertension, the SHRSPHD. METHODS AND
RESULTS: We conducted a further crossbreeding experiment between SHRSPHD and a congenic reference strain, WKYHD-1, that carries a 6-centimorgan (cM) long, SHRSP-homologous segment introgressed in chromosome 10, 26 cM remote from ACE. This allowed us to contrast effects on blood pressure and ACE activity conferred by the ACE locus with other more remote loci within the congenic chromosomal region. Genetic analysis in this F2 (WKYHD-1 x SHRSPHD) cross revealed that plasma ACE activity was determined almost entirely by genetic effects of the ACE gene locus (lod score = 43). However, neither plasma ACE nor the ACE locus showed any cosegregation with blood pressure before or after dietary NaCl exposure.
CONCLUSIONS: These results demonstrate that a molecular variant of the ACE gene determines plasma ACE activity but exhibits no direct effect on blood pressure. Moreover, the findings also exclude the possibility that plasma ACE is secondarily affected by blood pressure or excess dietary NaCl exposure. Our results reconcile the previous discrepancy between findings in human and experimental hypertension.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586334     DOI: 10.1161/01.cir.92.9.2381

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis.

Authors:  E Villard; L Tiret; S Visvikis; R Rakotovao; F Cambien; F Soubrier
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

2.  [Inpatient post-transplant services and intermittent rehabilitation in patients after kidney transplantation].

Authors:  R Templin; D Janek
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

3.  Rat Ace allele variation determines susceptibility to AngII-induced renal damage.

Authors:  Jelena Kamilic; Inge Hamming; A Titia Lely; Ron Korstanje; Ute Schulze; Wilfred J Poppinga; Anthony J Turner; Nicola E Clarke; Harry van Goor; Gerjan J Navis
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2011-07-25       Impact factor: 1.636

4.  Genetically hypertensive Brown Norway congenic rat strains suggest intermediate traits underlying genetic hypertension.

Authors:  Marijo Bilusić; Carol Moreno; Nadia E Barreto; Michael R Tschannen; Eugenie L Harris; William K Porteous; Caryn M Thompson; Murray R Grigor; Alan Weder; Eric Boerwinkle; Steven C Hunt; J David Curb; Howard J Jacob; Anne E Kwitek
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

5.  Differential ACE expression among tissues in allele-specific Wistar rat lines.

Authors:  Jelena Kamilic; A Titia Lely; Harry van Goor; Hendrik Buikema; Hilde Tent; Gerjan J Navis; Ron Korstanje
Journal:  Mamm Genome       Date:  2009-03-03       Impact factor: 2.957

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.